Centene Corporation filings document operating and financial disclosures for a government-focused managed care company. Form 8-K reports furnish quarterly results press releases, GAAP and adjusted EPS guidance, non-GAAP financial measure disclosures, conference-related Regulation FD updates and material-event reports tied to company performance.
Centene's proxy and governance filings cover annual meeting matters, board and executive compensation disclosures, equity awards, officer appointments and related corporate governance topics. Other filings address material agreements, forward-looking-statement disclosures and formal exhibits filed or furnished with the SEC.
Harris Associates L.P. and Harris Associates, Inc. file Amendment No. 1 to a Schedule 13G reporting ownership in Centene Corp. The filing shows Harris beneficially owns 20,418,731 shares of Centene common stock, representing 4.1% of the class. Harris reports sole voting power for 18,043,616 shares and sole dispositive power for 20,418,731 shares. The filing states these shares are held in the ordinary course of business and not for the purpose of changing control. The document identifies the filing parties, addresses, CUSIP 15135B101, and includes certifications and signatures dated 08/14/2025.
Centene director Kenneth A. Burdick filed an amended Initial Statement of Beneficial Ownership to correct previously reported holdings. The Form 3/A reports 360,802 shares of Centene (CNC) and states the original Form 3 filed on 01/14/2022 and subsequent Form 4s overstated his direct holdings by 29,533 shares. The event date listed is 01/05/2022 and the amendment was executed by an attorney-in-fact on 08/11/2025.
Centene Corporation director and chief executive officer Sarah London reported an open-market purchase of common stock on 08/08/2025. The filing shows acquisition of 19,230 shares at a weighted average price of $25.49–$25.50, increasing her reported direct beneficial ownership to 845,275 shares. The ownership total explicitly includes 591,998 shares represented by previously-granted restricted stock units and performance stock units reported at target levels and subject to vesting.
The report also discloses 13,449 performance-style stock options with an exercise price of $81.85, tied to a grant with a performance condition that the common stock close at or above $100 for 20 consecutive trading days before they may become exercisable. The form was executed by an attorney-in-fact.